Hello, everyone. So thank you for being here today. We will be covering a lot of ground. We will be giving a very brief intro to the company for those that don't know it, and then we'll jump straight into the update of what has been happening since the last webinar, which was about a month ago, and we will finally be covering the Tier Two warrant exercise, which exercise period started today. And of course, answering any questions that might be coming. So very exciting day, we will jump straight into it. Brain+ is a digital therapeutics company that is treating the cognitive decline of dementia. Dementia being one of the largest unmet clinical needs in the world today, and lacking effective treatment options. However, there is a great opportunity for digital therapies and and digital therapeutics is a new and explosively growing field in the healthcare space, which is a software program that treats a disease, and that is what Brain+ is developing for dementia. The digital therapeutics market potential within dementia is estimated at $5 billion today, and is expected to grow to $15 billion-$20 billion in the next 10-15 years. What we're also seeing in the digital therapeutic space is a number of major deals going on between digital therapeutics company and pharma companies. Brain+ is working with a therapy called cognitive stimulation therapy, and we have launched our first product, the CST-Therapist Companion, here in Denmark, which is supporting therapists providing this therapy, which today is being given in groups of 4-8 people. Launched in Denmark, this product that provides high-quality content to these therapists, saves them a lot of time, and ensures the quality, which is very important for the actual effectiveness of the treatment. This product launched in Denmark, introduced in Germany, and also will be launched in Germany next year with a second version, which is in the pipeline, which will be a much more advanced version than the first version that we have in the market, which we ourselves consider a bit of a minimum viable product. The second product launched in the first half of next year will have much more adaptive capability, and thus provide even more value besides the good cost-saving or time-saving value that we're already providing. Then we have our second product in the pipeline, the CST Home Care Solution, which for the first time, really will enable this therapy to be delivered in people's own homes, where they can do this therapy with a family caregiver, all of a sudden making this therapy available to many more people than it is available today. And this is where we expect a very large potential to be, which builds upon the potential of the first product. Just very briefly, the business model currently is a B2B or B2G, business to government, licensing model. So a software as a service model, actually here in Denmark. In the larger markets like the U.K., Germany, and the United States, it is a reimbursed model that we're going for, which means that health insurance companies and healthcare payers will be paying for each treatment delivered with this product. In terms of, competition, there are other types of dementia therapies. Some of them are being digitalized, but no other therapy has even close to the same amount of clinical evidence as does cognitive stimulation therapy, that Brain+ is the pioneer in digitalizing together with the leading KOLs who invented this therapy. And this is one of the reasons this therapy is recommended for global implementation, by the World Alzheimer Report of 2022. And that means that we have strong policy for support, the therapy being adopted in 37 countries around the world. And speaking of what's happening in digital therapies, here comes one of the updates. Brain+ was speaking at the DTx East Conference in Boston last week, which is the most important conference for digital therapeutics. Here are just some quick takeaways to share with you how is it going overall in the digital therapeutics market. First of all, I think one of the key takeaways is that the healthcare systems, also in the United States, even more so than in Europe, are under such enormous pressure that digital therapies and digital solutions to support the healthcare delivery is an inevitability, and is actually coming much faster than anybody's expected. The other thing is that the hype is over. You can say the market has already, based on the current market conditions, really normalized. And so digital therapies that are still here are the ones that will make it through and will grow to become a solid part of the future way of doing healthcare. Then something that everybody was in agreement on is, that it's important to go faster to the market than the life sciences have been used to, which is also what we've done here in Brain+ with our first product coming on the market two years faster than originally planned, and the same is what we're going for in other markets: to move faster, so we can create traction faster, start building brands, start building recognition, start building trust, which is what we have been doing here in Denmark and are also starting to do in Germany... and we'll be getting back to that. Of course, that rigorous clinical evidence is still the master key of success, and we will skip that, skip the rest here. I can encourage you to, to read some of my LinkedIn posts if you want more of the takeaways. Also, just mentioning very briefly that one of the strategies of Brain+ is to partner with pharma, and this is also what some of the most successful digital therapeutics companies have been doing. Here we see that cognitive stimulation therapy that we are working with, combined with Alzheimer's medicine, is actually enhancing the effects of the drugs, which is very promising. And I want to restate, this is a long process, getting in with these big pharma companies, but we have ongoing pharma talks with some of the big pharma companies that are active in the Alzheimer's space. And this is something that we believe will be a key part of the future of healthcare, is the combination of both digital therapies that are synergistic with drug therapies. Then on another piece of news, since the last investor update, we have a new board member, Anish Shindore, who is, probably, I would say, as I've just been in the United States, this is a home run in terms of if I had to pick one person from the entire industry to get on my board, it would be Anish. Anish has been the Head of Digital Therapeutics at Novartis, at Sanofi, and latest at Biogen. Biogen being one of the leading Alzheimer's pharmaceutical companies in the world. He's one of the people who has done the most pharma and DTx deals, in the industry, including also, acquisitions of digital therapeutics company, investments in digital therapeutics companies, co-development deals, licensing deals. We have nominated—Anish has been nominated for the board seat, and if everything goes as expected, we will elect him next week. So Anish is really a thought leader on all the big DTx conferences and in the entire digital health community. Very respected, very listened to by healthcare providers and healthcare payers, respectively. Another quick update here is on the grants that we applied for in July. We have put out news about this. I think two of these grants have passed through the first evaluation gate and with unanimous evaluator support, which in itself is an achievement. You actually only need two out of four evaluators to pass to the final gate, and we had four out of four give the thumbs up, including with some very nice remarks about the potential and the necessity of the solution. This was for the EIC Accelerator, which is the biggest of the grants we have applied for. It's a DKK 60 million total submission, of which about 20 million is grant money, and the rest of the 40 million is equity funding coming from the European Central Bank. If we get the grant, you also get the commitment from the European Central Bank. So this is great news that we have moved on, and I think we will have a question on that later actually. What has also happened in the meantime is that we have gained additional support from not only the inventor of CST, University College London, who are part of this, who will be part of this application, also the NHS, in the form of what is called the NHS trusts, who will be sites where we will pilot the CST home care product. That was the second product I showed you before, which is the one that we are applying for grant funding for developing and clinically validating. So great that we already have several NHS trusts that are interested in basically collaborating with us on this project. Also, a new development is that we've gained the support of Alzheimer's Disease International, which is the global Alzheimer's disease organization that has all the other national organizations as members. They are the ones doing policy about Alzheimer's on a global scale. So the most on a global scale important Alzheimer's patient advocacy group. And so we're very happy that they're also providing support for the project. The same goes for the European Brain Council, which is a leading policy group here in Europe, really in depth with all of the physicians and the clinicians in Europe. And so they're very good to have on board in terms of creating awareness, trust, and recognition of the work we're doing. And one that's so new that it's not even on here is the European Federation of Neurological Associations, which is the umbrella organization for all patient advocacy groups of neurological associations. So really, we're having a lot of support for this project, and that is a great plus in terms of actually winning that grant. We also, in the meantime, won a smaller DKK 50,000 grant. grant. That's a really small one compared to the other ones, but it just shows that we are continuously having momentum in the grants. And I'll save the rest for the question for later. Finally, I think we have had a busy time, and we're having a busy time the next couple of months. Brain+ is really becoming, and have been for some years now, a thought leader within digital therapeutics and dementia. So we are both represented at the premium life science conferences. This is an example of the two Nordic ones, Nordic Life Science Days and LSX, which in my opinion, is some of the premium life science and investor conferences, in the Nordics, where we are being invited to speak at panels and present what we're doing. We are also at the major tech conferences. We are invited to speak at the major digital therapeutics conferences, both the one in Boston, we were at the one in London previously this year, we are at the one in Berlin. We are not paying anything to be there, we are being invited because we are seen as some of the thought leaders in the field. The same goes for the dementia conferences. We'll be present at Alzheimer's Europe, their conference in Helsinki. We were at the Danish Dementia Coordinators Conference, which is a really, the most important conference for, dementia caregiving in, in Denmark, you can say, and the INSIGHT-DEM, which is the leading, organization of, of, physicians and scientists in dementia in Europe. It's about early detection and timely intervention in dementia, is what this, this, organization is about, and this is their annual conference that we are also participating in at the end of this month. So really, we have a lot of visibility out there, a lot of recognition that we are, of course, turning into traction in the markets that we are entering with our products, which is particularly obvious in, in the U.K., as we'll get back to, and also in the, in the United States, which is one of the future markets that we have our sights on. Then a brief, like, look at some of the expected milestones and events for this year and how we're going. First, we have executed IP protection. We made an announcement of this earlier in the month. And that means that we now have design protection in a number of our key target markets, which is very important to fortify our commercial position. Then we will soon be coming out with some more details on the trial that will be happening this fall. And there, we have finalized the development of the second version of the CST-Therapist Companion for the clinical trial. The market-ready version will come in the first part of next year, but we have finished the version that will go into this clinical trial of the fall, which what was this milestone was all about, and we have initiated the development of the second product, the CST Home Care. For the rest of the year, we will have this clinical trial starting. That will be within the next couple of months, and it will be finalized before the end of the year, so we'll get results on that. We are also planning a usability study in Germany, and we are getting ready to make the second version of the Therapist Companion a medical device. Right now, it's a non-medical device support tool for therapists, but the second version will be a medical device Class 1 under MDR, which again, is a big door opener for a number of partnerships, for things like reimbursement, and it's a stamp of quality, of course. We are also starting clinical pilot studies with our technology for cognitive training in healthy elderly and elderly people with Mild Cognitive Impairment. And finally, we're expecting some partnership agreements to materialize this year. So these are the expected milestones within technology and product development. Then we have some financials that we will talk about a little bit later, and we will also actually be announcing this week, the introduction of a version 1.2 of the Therapist Companion. This is an intermediate release, which includes a number of new, feature updates and improvements on the current product in the market. And this takes into account a lot of the things that we have not only learned from being live in the market with customers, but this is also a number of, user experience improvements that our customers have asked for, that are, that are actually already live. And we will be coming out with some more details of it, this week in, one of our news announcements. And then, of course, we are expecting, to close more sales contracts this year in Q4, as we have been talking about. And let me jump straight into that. In terms of what is happening, what is the commercial plan? Again, here, nothing really is changed compared to what we have been saying all year, is that the municipal sales cycles is such that sales happen primarily in the fourth quarter of the year. So this is the quarter that we're entering now, and this is when the municipalities have the budgets that they will finally spend, you can say. So we are expecting to seeing sales here as a continuation of some of the early sales that we actually were successful to get earlier in the year. We have a strong pipeline, and at the DKDK, the Dementia Coordinators Conference this month, we really saw, again, much more recognition of both Brain+ and Cognitive Stimulation Therapy than we experienced last year. So we really see that the early market, the sales, communication, and branding work that we've been doing is paying off, and this is why it's been important to come out early for us, to really start building that trust in the product, and we'll see the first of that, we expect in Q4, the effects of that. And also, of course, next year we'll see that pick up even more strongly, is our clear expectation. That's on the Danish side. I'll actually start with the German side, so pardon the sequencing here. On the German side, as well as the Danish actually, we are working on getting our products into the CST educations. As if you have followed us before, you will know that to do Cognitive Stimulation Therapy, a therapist needs to go through a formal education. It's a 1-day education, and we are working now, both in Germany and in Denmark, and having also talking about it with University College London, to basically integrate our product into that education. We are doing the very first prototype of that actually today here in Denmark with the first, 12 therapists. They are going through an integrated education that has our product as an embedded part of being trained in Cognitive Stimulation Therapy. This gives us a unique competitive position where all new therapists will be trained directly in our product, and that is basically happening in all the key markets. This is important because not any educational institution can train new therapists. These are designated institutions that are selected by the University College London, and only those educations can actually train new therapists, which gives us a unique competitive position in all of these markets. In the United Kingdom, we are preparing for next year, where we expect to launch the product. That is both in terms of doing the local pilots there, and as you could also see from the previous slide, there we are very far with the NHS trusts in terms of actually basically helping us do the first local pilots there, not only with the home care product but also with the Therapist Companion, and we are talking to U.K. distributors. As you may remember, while in a country like Denmark, we are using our own sales force, in other markets, we will partner with distributors, and there are specialized digital therapeutics distributors that are basically adept at selling digital therapies into markets and into healthcare systems like the NHS. So again, this is a process that doesn't happen overnight, which is why we're starting early with these talks and in finding the right partners for the U.K. And then just a brief mention on the overall plan. We won't go into this in too much detail today. You can also watch our previous investor webinar, where we discuss this in more detail, or you can read about it in our half-year report, which summarizes some of these things. But I wanna mention here that what... As we expand from Denmark, Germany to the U.K., we're also really setting our sights in the longer term on the biggest healthcare market in the world, which is the United States. It is also the market, a market where our Cognitive Stimulation Therapy is gaining a lot of traction, and we have some interest from a number of KOLs over there. Again, we generally start markets by partnering with key opinion leaders and thought leaders, which is very important for getting the local clinician and patient community on board. As you can see, we're also generally very experienced and have a good working relationship with the patient advocacy groups. And in terms of getting adoption of new digital therapies, the one that have been the most successful are the ones that actually have strong support from the patient community. So we are really laying the early seeds also for, for the U.S. market, while right now, the without a doubt, the priority of our focus is going to Denmark, Germany, and the United Kingdom. And that is a brief summary of both the company, some of the latest updates, what is to come the rest of the year. And then I will basically hand it over to our CFO, Hanne, who will talk a little bit about the TO2 exercise and what has happened leading up to that. I'll just mute myself here. Good. Thank you, Kim. I would actually like to start and go back to the IPO. So when Brain+ was public or went public in October 2021- Sorry. It was at a value of DKK 40 million. We went to the market with a very clear plan to develop our pipeline and get new digital therapies out to the market in order to help meet that immense need we see in the dementia market, and to help people with dementia, their caregivers, and also clinicians better be able to cope with that enormous challenge. Since then, as Kim has explained, we really believe that we have advanced. We have advanced the pipeline, we have made a number of collaborations, we have made close ties with market market actors in Denmark, in Germany and in the U.K. We have also launched pilot versions of our first product in order to get that go-to-market experience, and as Kim said, to have our customers be accustomed with our product and give us feedback. So we really believe that we stand in a unique position, and unfortunately, this has not been reflected in our share price, and we're very aware of that. We are also very aware that our very trustful, or how can we say, loyal shareholders has not made a gain. We do believe that there is a bright future. We also do believe that with the amount of milestones and events that we see in front of us, that this will change. We have currently 28.5 million TO2 warrants outstanding, and these TO2 warrants were issued in connection with the unit rights issue we did in April this year. So a unit rights issue is actually an offering of units, meaning that you subscribe for both shares and then also for warrants, and in our case, warrants of TO2 and TO3 series. Now the TO2 warrants have become exercisable. They're exercisable at a price of DKK 0.2, and they can be exercised in a period starting today and until the sixteenth, so the end of next week. We in board and management, who subscribed in the unit rights issue in April, we have this morning committed, or we announced this morning that we have committed to subscribe to all our warrants, which amounts to a combined additional funding in the company of DKK 0.2 million. If you want to subscribe for warrants, those of you who may already hold TO2 warrants, you will get notified by your custodian bank, and you shall then just act as they guide you to. If you do not hold TO2 warrants, they are tradable in the market and can be bought and sold, exactly as shares. And, you can only subscribe for new shares at the DKK 0.2 share price if you have warrants. So I think with that, there's also maybe I should say that on our website, there is a frequently asked questions document, where there's more in terms of explanations of the TO2 warrants, what they are, and how to exercise and how to act. And we're, of course, always here for any questions you may have. Yeah, and if you're not already subscribed to our newsletter, I would encourage you to sign up for that, where we'll also be sending out this Q&A. And often I send my personal investor updates out through that channel. So I encourage you to sign up for that. That comes at a regular frequency. There was one coming out last week, also in preparation for inviting for this event. So I can highly encourage that. I think what I would like to probably summarize in terms of where we are now. Hanne mentioned a bit of this since the IPO, but just zooming all the way out and looking at where Brain+ is, we really have a unique, advantageous position. We are- Anders, can you hear us? Because we seem to... I can hear you now, yes. You lost sound around five or 10 minutes ago. I couldn't get a hold of you, so we need to get back to Kim's presentation. Hmm. It's not working. Hello? Hello. I can hear you, Kim. Okay. Where did you go? We lost your presentation around five or seven minutes ago, just after Hanne was over with her presentation. ... Okay, just when Hanne finished her presentation. Good? Yeah. Good. Fine. Apologies for that. I think we'll cut out those five and seven minutes. But basically then, let me summarize here what I was doing. That was just a brief summary. I think, building on what Hanne was saying, Brain+ is in my opinion in a really unique position. We have a quite advantageous first mover position as the pioneers in digital evidence-based dementia therapies. And we are as the leaders, you can say, working with the leading non-pharmacological dementia therapy today, Cognitive Stimulation Therapy. And so this is a therapy that has no rival in terms of clinical evidence. We're working with the leading KOLs in this area. So we are integrating into the educations of new therapists with our product, again, putting us at a really strong position where all new therapists will be trained in our product. We are coming to the market quicker than planned, and we will continuously be looking to get onto the markets as quickly as possible. We are building very good momentum and recognition in the markets that we are active in, in particular in Denmark, where we have been active the longest, and we're expecting to see the fruits of that in the coming six months. I think it's an exciting, really exciting six months ahead because we will be hitting some key value inflection points. We will be building on the first early sales, which are great, but what really is important is that we can keep showing that momentum, and now entering the buying season of our customers, this is where we expect that to be happening. We also expect to see the fruits of some of our long, ongoing partner dialogues in the Alzheimer's space, basically bear fruit within the next six months time. We have clinical trials, and there will be results, more results coming out, specifically with the products that are now in the market, where our previous clinical trials, which have been successful, have been with the technologies, now the trials are with the products. So this is also something that will make a big difference. And we will also be looking to upgrade the first product to a Class 1 medical device under MDR, which will be something that unlocks a lot of potential for us. So really an exciting six months ahead, in my opinion. And I think we have seen, based on how the financial markets have gone, we are basically, in my personal belief, this is a very interesting time to consider becoming a shareholder. If one is a shareholder already, it's an interesting time to consider exercising one's warrants, of course. But if you're new to Brain+, this could be a very interesting time to look at us based on the position and what we have built up until this point, and what's gonna happen in the next six months. With that said, I think we will spend the last minutes for the questions and answers. Perfect. Thank you for that, both, Kim and Hanne. Let's move directly into the questions. So the first question here: What is the estimated chance of getting the EIC Accelerator application approved? In the case of approval, how will the grant be paid out? Is it paid out upfront, or do you need to have the capital to make the investments and afterward get it covered by the grant? Yeah. So that's, that's a fine question. Let me try and add a couple of data points to that to make it a little bit more concrete. One thing is that we're not doing this alone. We're working with a very talented, you can say, a consultant company called Dealflow, which we have worked with before, which is also the ones that we won our last big E.U. grant with, which was for EUR 1.5 million, which was the Act Now project. So we're working with them again, and their overall hit rate for grants is 70%, which means that of all the grants that they help writing, they get 70%. They don't necessarily get them in the first submission, which means that maybe they need to get through the first submission, get feedback, and then do a second submission. So there can be multiple submissions before you get it, but you do get it eventually. I think we have, based on the first-round evidence and based on their feedback to us, this was in the very good end to have all four evaluators evaluate positively the grant. Of course, again, there are no guarantees. But based on the 70% overall hit rate, I would say the hit rate to get it in the first go is somewhere in between, what do I know exactly? 30%-70%. But that's of course a very rough guess from my side. I think we have so much experience with grants, which is another advantage. DKK 72 million worth of grant funding have gone into our pipeline and our R&D processes to date, and so we've won this type of grant before. We know the process, we know what they're looking for, so in that way, we're in a better position than a lot of other companies. We're also in a better position from the point of view that we have such strong collaborations, such a strong track record, going on, and that is also something that the evaluators are looking for. So that's on the one side. On the payment profile, the way that the E.U. grants usually work is that you get a quite a large sum paid out upfront, and then the rest will be paid out every six months, usually, based on the cost incurred. And then at the very end of the project, the overall tally is made, and you see how much is used. And so usually in the last period, there is... You're spending what you got paid out in the prepayment. So you actually get a prepayment before the project starts. So it's something that can be very helpful to cash flow. Perfect. So- No, use this so we don't- Yeah, okay. Just speak here. Just speak loudly. To be precise, if we are so lucky that we actually get the grant application approved in the first instance, we can start see cash flow from the grant in the first quarter- Perfect of 24. Yeah. The next question here: Can you give an update on the German Malteser Hilfsdienst pilot program? Has the program started, and what is the potential feedback, and when is the pilot set to finish? Is there a probability that this can turn into a paid deal after the pilot program, or is that not part of the discussion so far? Yeah. So right now, what is happening in Germany is that we have now involved the KOLs also with the dialogue and the pilot with Malteser Hilfsdienst, which is actually, in our case, the best, the win-win scenario. Because one thing is to get a provider like the Malteser Hilfsdienst involved, but even better is if you get the provider and the KOLs, the clinicians involved, and then do it together with them. So that's basically what we are trying to design now, together with the KOLs in Germany and with Malteser Hilfsdienst. So we've done some early work with Malteser Hilfsdienst, but nothing in terms of any results coming out yet. What we're doing now is we're planning with the German KOLs how we can involve Malteser Hilfsdienst in a more structured trial that involves the German KOLs. Related to that is also the German CST education. We have been, as you might remember, co-developing the German product version with the German KOLs, and based on that work, I think, which is very positive, they have evaluated that the product is turning out up to be of such quality that they want to integrate it also in their education. All of these things are now kind of fitting together, just like we're doing here in Denmark, where the CST education, the integrated CST education, is actually the beginning of the new trial that will be happening here in Denmark in the fall. I expect that we could be seeing something similar, in Germany with Malteser Hilfsdienst, where we can look at integrating the education for the therapists there and then run the larger trial with them. And to the latter part of the question, I would say yes, that is a possibility. Of course, how big, how much? I can't say anything about that right now, but yes, it is a possibility that it turns into a paid engagement. That is definitely what we try to do with all the pilots that we have, because these are usually customers, potential customers, that we wanna get onto the product eventually, of course, and paying for it. The next question goes like this: As I understand it, the CST program has 14 sessions. Does that mean the treatment only lasts these 14 sessions, or what happens afterwards? Will the patient be able to start over again, or do they need to find another program or treatment method afterwards? Do you expect to be able to treat dementia patients for a longer period of time in the future? Yeah, that's a, that's a great, and important questions actually. So CST can actually go on indefinitely, but the first 14 session is part of what is called the basic CST program, which is usually seve weeks with two sessions per week. That's what give you the, the 14 sessions. And it's based on these seven weeks that we're seeing all these cognitive improvements, improvements in quality of life, improvements in communication. So in that way, it's a quite fast-working, treatment, you can say. But the recommendation is to keep doing it. So that... And, and this is called maintenance CST. And, and so this maintenance CST can both be done in a clinic, that's what happening, for example, in, in the U.K. People will keep coming to the clinic, and they will get maintenance CST. But this is where in a lot of places, the CST treatment offering to the citizens actually stops after the first basic treatment. They don't get an offering for the continuation. And why? Because there's a lack of hands in the healthcare system to actually deliver that. This is where our second product, the CST Home Care, comes into the picture. The whole idea with that is that the people with dementia can continue doing this therapy indefinitely. So that is basically the answer to that. We do expect to be able to offer CST on an ongoing basis to people, so they don't need to look for anything else because, quite frankly, CST is the best there is. So, so that therefore it would only make sense to keep delivering it to them and for people to keep using it. Maybe adding to that, that's also one of the cases or one of the aspects where the dementia specialists, they see to the digital version of CST as being a very important tool in order to scale and extend sort of the CST treatment. Because that is, as Kim says, there's not hands enough in the healthcare system, so that we can actually, via the digital delivery platform, ensure access to using this continuously at home is a major advantage. Perfect. Then there's a question here from Jenny, "Will those that have subscribed for version one of your CST program be automatically upgraded for the version two, or do they have to buy licenses to get upgraded from version one to version two? So that depends on individual negotiations with them. They will not automatically be upgraded, that depends on what we are willing to offer them. Generally, the version two is much more valuable than the version one, so we do expect to negotiate with customers if they want access on that to the version two. Perfect. And the next- Because just to be clear on that, because the contracts that we've made only gives them access to version one. It doesn't automatically give them access to future updates. Okay. And the next question here, "When you tell you are expecting partnership agreements, does that mean you are currently in negotiation with some potential partners? The short answer is yes, that we are in quite progressed discussions with potential partners. When I say that, it means that we have been doing this, not something we started a month ago. Some of these dialogues actually started over a year ago. Okay. And the next question here, "On the sales contracts, do you expect to close deals at a price representing a pilot sale or a full sale? Meaning, do you expect to get big discount on the upcoming sales, or are you fully priced in now? No, right now we are doing sales to get our foot in the door, so these are not full price sales at all. This is really the early investment to build reference customers, which is a necessity. Even all companies need to do that. Even the best performing company on Nasdaq First North have started by doing big discounts to build reference customers. And so that's what we're doing, and this is very deliberate. So this is not the period of big revenues, it's a period of traction and building reference customers. Then we can start pricing it more fully. This also actually goes back to the previous question to say, will there be a rollover of a contract? So if there will be that, and it will be from the current version to the next version two, it will be at a very different pricing. So to reflect that this version two product actually has, as Kim has explained, much more features, much more content, the customizable sort of version, and the options for, for therapists. So, a very different product and therefore also a different pricing. Perfect. And then we have the last question here from Jenny, "Would your CST programs require FDA approval to be available in the USA? That, I would say that depends, and it depends on the claims we wanna make. And so that's a little bit like in, in Denmark, or in the E.U., that, if we want to claim that it's a treatment, then the answer is yes. But there are other avenues where you don't make such claims, where it will not require an FDA approval. No matter what, we will do regulatory work to ensure that whatever we do is of course, okay within the regulations. And we do expect to engage with the FDA because we do see that there can be a big value also in being FDA cleared as a, as a medical device in the United States. But is it a requirement? Well, that depends on what on how you choose to go to market with that product and what the intended use of the product is. That was all the questions. Before we end the webcast, I will hand over the mic for you for some final remarks. Yeah. So again, apologies for the lack of sound before. I think, personally, I think we're... I'm very excited in terms of the position that we are building and how things have been developing this year. I think they're developing very positively in terms of the feedback and responses we're getting directly in the market, the interest that we're getting, the partnerships that we're building, the competitive position that we have now improved, both on the IP side, but also in terms of basically integrating, beginning the integration into the CST educations. So really, I think we're in an absolutely unique, advantageous position here that is only a matter of time and execution before we will really start, seeing that take off. So that was my final words. You want any final words on the- I just want to, from my side, to thank you very much for your interest and for listening in to this. And again, encourage you if you have any doubts or questions relating to the warrant exercise or anything else relating to our company and outlook, please reach out to us. And one final practical note, I think, which I just want to mention, because last warrant that we exercised, where we had a very successful exercise rate, a lot of warrant holders weren't aware that a bank like Nordnet actually requires the money to be in the account a few days before the closing of the warrant exercise period. So please go check your corporate action in your bank, not at the last minute, so that you make sure that you know what your bank's deadline is, because that can be several days before the closing of the exercise period. So that's just a small note on that one. But otherwise, also, thank you so much for your support from our existing shareholders. It's a really an honor to have you with us on the journey, and of course, we welcome any new shareholders who are interested in joining us on this mission to help people with dementia around the world. Thank you so much and have a wonderful day. Thank you. ... and week.